
# **Case discussion**



## 王江OO 17735F, 68 y/o F

- 2018/12/20 (CS OPD): chronic cough and burning sensation for 2 years, s/p LMD EGD proved hiatal hernia
  - arranged Chest CT and Chest with Barium



## 王江OO 17735F, 68 y/o F

- 2019/01/16 (GI OPD): Chronic cough for months, especially when lying down.
  - Heartburn sensation (+) despite regular PPI use for one month
  - Dysphagia (-); BWL (+, from 48 to 42 kg in two years)

_ 處方名稱	天數	劑量	單位	頻次	途徑	Ī
10mg Singulair tab	7	1	TAB	HS	PO	'D for
- Acetylcysteine tab Ġ	7	1	TAB	QN	PO	
🕻 Avamys nasal spray	7	4	PUF	QD	NA	
XyzaL tab 5mg	7	1	TAB	QD	PO	_

## 王江OO 17735F, 68 y/o F

- 2019/01/17 (CM OPD): r/o bronchial asthma
  - arrange <u>Pulmonary Function Test</u>, with asthma inhaler adjustment

#### CONCLUSION :

Severely obstructive ventil 塞性通氣障礙 》	latory imp	pairment.		《重	度阻						
以上結果為吸藥前測試 Positive bronchodilator res 氣管擴張反應 》	sponse.			«	陽性						
				處	方名稱	₿.		天數	劑量 單位	頻次	途徑
				Fo	ster inh	120dos	se	28	2 PUF	BID	INH
					ntolin i	nhaler		28	2 PUF	TIDPR	IH
	PULMO	NARY LA	BORATO	XY —							
F-V LOOP		PRE-RX			POS	ST-RX					
SPIROMETRY (BTPS)	PRED	ACTUAL	%PRED	ACTUA	L %	PRED	%CHG				
FVC LITERS	2.27	1.71	75	1.91	84	12					
FEV1 LITERS	1.83	0.55	30	0.66	36	19					
FEV1/FVC %	N/A	32		35							
FEF25-75% L/SEC	1.96	0.15	8	0.18	9	21					
FEF25% L/SEC	4.60	0.40	9	0.52	11	29					
FEF50% L/SEC	2.71	0.17	6	0.21	8	27					
FEF75% L/SEC	0.68	0.08	12	0.07	11	-7					

# 王江OO 17735F,68 y/o F

- 2019/02/20 (GI OPD): delay motility testing due to severe obstructive lung disease
- 2019/03/06 (IMRH OPD): for skin eruption in both palms, s/p <u>I.M. steroid injection</u>
- 2019/03/20 (GI OPD): BA is most likely, given a dramatic improvement of cough after steroid use

處方名稱	天數	劑量	單位	頻次	途徑
Methasone inj 5mg Ġ	1	5	MG	STAT	IM
Metholone tab 16mg Ġ	14	1	TAB	QD	PO

## IMRH survey, 2019/02/21

#### ANA

申請序號:	A3357049 檢驗項目: ANA (blood)
原始報告:	http://fs01.vghtc.gov.tw/lis/ANA/20190222/8000518177.pdf
	ANA result : Negative
	Titer :
	Nucleoplasm :
	Nucleolus :
	Cytoplasm :
	Chromatin :
	Mitotic cell:
參考值:	Positive: $\geq$ 1:160


#### SSA, SSB Ab

申請序號: A3357051   檢驗項目: SSA, SSB Ab
SSA Ab: Negative ' < 0.3 EliA U/ml
SSB Ab : Negative ' < 0.3 EliA U/ml
SSD AO. Tregauve CO.S Ear Onlin
参考值: Negative : < 7 EliA U/ml Equivocal: 7-10 EliA U/ml
Positive : > 10 EliA U/ml


#### C3 (blood), C4 (blood)

申請序號:	A3357050	檢驗項目: C	〔目: C3 (blood),C4 (blood)			
	C3 (blood):	122.8	mg/dl	(C3 : 87-200 mg/dl)		
	C4 (blood):	22.1	mg/dl	(C4: 19 - 52 mg/dl)		
	參考值: C3: C4:	87- 200 mg/dl 19- 52 mg/dl				

#### HRIM, 2019/05/16



#### HRIM, 2019/05/16




#### Manometry, 2019/05/16

HEIGHT: 151 WEIGHT: 43	VALUE	NORMAL RANGE
RESTING PRESSURE OF LES	16	10-40MMHG
LOCATION OF LES	36.5	
LENGTH OF LES	4	2.4-5.5CM
INCOMPLETE RELAXATION OF LES	<5	~90% OR RESIDUAL PRESSURE>5
AMPLITUDE	45	13CM: 70(+/-)32MMHG
	58	8CM: 90(+/-)41MMHG
	78	3CM:109(+/-)45MMHG
MORPHOLOGY (DOUBLE OR TRIPLE PEAK S)	1	
PROLONGED DURATION OF PERISTALTIC WAVE	<6	>6SEC
SIMULTANEOUS PERISTALSIS	0	<10%
NON-TRANSMITTED PERISTAL SIS	0	<20%
NOTES: HRIM C.Cv3.0:40% Ineffective contract contraction. IRP:11.04, DCI:542 r/oType III(a) Hiat separated 2.8-3.0cm	-	

IMPRESSION: Normal esophageal motity profile.

#### 24hr-pH (off PPI), 2019/05/16



AOI=S 在日記上的症狀


### 24hr-pH (off PPI), 2019/05/16

DeMeester score: 6.19 (14.72 is upper limit of 95.0 percentile of normal)


#### Adult scoring graphs

Score component	Patient Normal
Total reflux time (Total)	2.2 < 4.3 • 20 Total %
Total reflux time (Upright)	3.0 < 6.3 • 20 Upright %
Total reflux time (Supine)	0.8 < 1.3 20 Supine %
Nr of reflux periods	22.0 < 50.2 • 100 in 24 hours
Nr of long reflux periods > 5 min.	0.0 < 3.2 20 in 24 hours
Longest reflux	4.8 < 9.3 • 60 min
FRACTION TIME OF PH < 4.0=DEMEOSTER SCORETHIS IS A PH TEST WITH 2 PHDISTAL ESOPHAGUS, RESPECTIVEPPI DURING THE STUDY.SHE REPORTED NO SYMPTOM DURSUGGESTING A LOW POSSIBILITY	= 10.65 (NORMAL 14 ~ 15) H SENSORS LOCATED AT PROXIMAL AND VELY, WHILE THE PATIENT WAS OFF RING THE RECORDING PERIOD.


#### Laparoscopic fundoplication, 2019/08/16



#### HRIM (post OP), 2019/12/03



#### HRIM (post OP), 2019/12/03



## Manometry (post OP), 2019/12/03

HEIGHT: 149 WEIGHT: 42	2 VALUE	NORMAL RANGE
RESTING PRESSURE OF LES	20	10-40MMHG
LOCATION OF LES	37	
LENGTH OF LES	4	2.4-5.5 <b>CM</b>
INCOMPLETE RELAXATION OF LE	<b>S</b> <5	~90% OR RESIDUAL PRESSURE>5
AMPLITUDE	15	13CM: 70(+/-)32MMHG
	99	8CM: 90(+/-)41MMHG
	52	3CM:109(+/-)45MMHG
MORPHOLOGY(DOUBLE OR TRIPL	E PEAKS) 1	
PROLONGED DURATION OF PERIS	TALTIC WAVE<6	>6SEC
SIMULTANEOUS PERISTALSIS	0	<10%
NON-TRANSMITTED PERISTALSIS	0	<20%
NOTES: HRIM C.Cv3.0:100% NORMAL CONTRACTION.IRP:12.08,DCI	:967,DL:7.2.Post Fund	oplication.

IMPRESSION: Normal esophageal motlity profile.

## 24hr-pH (off PPI, post OP), 2019/12/03

DeMeester score: 59.82 (14.72 is upper limit of 95.0 percentile of normal)

Adult scoring graphs	
Score component	Patient Normal
Total reflux time (Total)	13.5 < 4.3 • 20 Total %
Total reflux time (Upright)	19.8 < 6.3 20 Upright %
Total reflux time (Supine)	8.4 < 1.3 • 20 Supine %
Nr of reflux periods	209.6 < 50.2 100 in 24 hours
Nr of long reflux periods > 5 min.	11.3 < 3.2 • 20 in 24 hours
Longest reflux	53.0 < 9.3 • 60 min


FRACTION TIME OF PH < 4.0=</th>--% (NORMAL 4.0 ~ 4.5 %)DEMEOSTER SCORE=--(NORMAL 14 ~ 15)THIS IS A PH TEST WITH 2 PH SENSORS (10CM APART), LOCATED AT<br/>DISTAL ESOPHAGUS 5 CM ABOVE EGJ (32 CM) AND MIDDLE<br/>ESOPHAGUS, RESPECTIVELY, WHILE THE PATIENT WAS OFF PPI<br/>DURING THE STUDY.HE REPORTED NO SYMPTOM DURING THE<br/>RECORDING PERIOD.THIS WAS AN INCOMPLETE STUDY DUE TO THE PH<br/>PROBE WAS BROKEN THE PH SENSOR POST CALIBRATION FAILURE).

## Patient reported outcome (PRO)

- The Reflux Symptom Index (RSI)
- Reflux Disease Questionnaire (RDQ)
- The **GERDyzer**

		2019/3/6 Methasone inj ↓				2019/8/16 胃折疊術 ↓				
	108 1/17	108 1/24	108 2/18	108 3/18	108 4/17	108 5/16	108 5/23	108 12/3	112 8/2	
用藥	Singulair, Acetylcy steine, Avamys nasal spray, XyzaL	Singulair, Takepron	Singulair, Takepron	Singulair, Takepron	Singulair, Crestor	Singulair, Crestor	Singulair, Takepron, Crestor	Singulair		
RSI 總分 (0-45分)	28	31	32	24	25	26	21	13	3	
RDQ 總分 (0-40分)	9	12	29	9	15	2	10	2	0	
GERDyzer 總分 (0-70分)	51.3	56.5	61.3	29.9	33.3	47	23.5	7	0	

#### Common Causes of Chronic Cough and Multiple Causes May Exist in a Patient



Irwin 2006 Chest




Figure 4 Esophagogastric junction (EGJ) morphology subtypes. For each panel, the instantaneous spatial pressure variation plot corresponding to the red line on the pressure topography plot is illustrated by the black line to the right. The two main EGJ components are the LES and CD, which cannot be independently quantified when they are superimposed as with a type I EGJ (A). The respiratory inversion point (RIP), shown by the white horizontal dashed line, lies near the proximal margin of the EGJ. During inspiration (I) EGJ pressure increases, whereas it decreases during expiration (E). Type II EGJ pressure morphology is illustrated in B. Note the two peaks on the instantaneous spatial pressure variation plot; the nadir pressure between the peaks is greater than the intra gastric pressure. The RIP is at the level of the CD. C and D correspond to type III EGJ pressure morphology defined as the presence of two peaks of the instantaneous spatial pressure variation plot with the nadir pressure between the peaks equal to or less than intragastric pressure. The RIP is at the level of the LES in IIIb (D).

#### Kahrilas Chicago v3 2015 NM




Figure 3. Time to primary symptom recurrence by preoperative response to AST.

## Key message from our case

- Chronic cough can be a combination of multiple causes
  - BA, PNH, GERD
- **GERD** diagnosis should be confirmed in multiple aspects
  - typical / atypical symptoms, high dose PPI responsiveness, AET
- Anatomical factors should be evaluated in early phase
  - risk of malignancy, hiatal hernia
- Motility survey can provide promising diagnostic support in specific cases
- Surgical prognosis should be carefully discussed in Acid-Suppression Therapy (AST) non-responsive patients

# Thank you for listening